Epic Bio

Epic Bio

  • Founded: 2018
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Facioscapulohumeral muscular dystrophy
  • Drug types: GEN, MUS, CVV, OPH
  • Lead product: EPI-321
  • Product link: https://epic-bio.com/pipeline/
  • Funding: $55M A Jul 2022



job board

Short description:

Therapies to control gene expression

Drug notes:

EPI-221 RD heterozygous familial hypercholesterolemia; EPI-241 RD alpha-1 antitrypsin deficiency; EPI-141 RD retinitis pigmentosa 4; EPI-111 RD retinitis pigmentosa 11

Long description:

Epic Bio is developing ultra-compact therapies to modulate gene expression and treat complex disease. Epigenetics play a key role in the regulation of which genes are expressed within a cell. By leveraging the epigenome, Epic has built their “mix and match” Gene Expression Modulation System (GEMS) platform that can combine epigenomic modulators to create therapies customized for specific disease indications. Part of their toolbox includes CasMINI, the smallest and most deliverable dCas protein to work in human cells. This offers Epic even greater potential for in vivo delivery and multigene disease treatment.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com